Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue

Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue

The invention relates to the use of cells from cell lines, which are derived from early embryonic stages, for the donor-specific increase in transplantation tolerance and for repairing damaged tissue. Areas of application of the invention include the field of medicine and the pharmaceutical industry...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Binas, Bert, Bader, Michael, Chai, Giuxuan, Faendrich, Fred, Ganten, Detlev
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Binas, Bert
Bader, Michael
Chai, Giuxuan
Faendrich, Fred
Ganten, Detlev
description The invention relates to the use of cells from cell lines, which are derived from early embryonic stages, for the donor-specific increase in transplantation tolerance and for repairing damaged tissue. Areas of application of the invention include the field of medicine and the pharmaceutical industry. The aim of the invention is to produce a donor-specific immunotolerance in order to prevent a rejection of the transplanted tissue due to an immune response and thus to be able to limit the administration of immune suppressive agents. In order to produce a donor-specific immunotolerance, embryonic stem cell-like cell lines (ECL) are obtained from blastocysts and are transfected with genetic material of the donor, which codes for the MHC haplotypes. The cells produced in such a manner are administered to the recipient before the transplantation for producing an immunotolerance against the tissue to be transplanted or for regenerating already damaged tissue.
format Patent
fullrecord <record><control><sourceid>uspatents_EFI</sourceid><recordid>TN_cdi_uspatents_applications_20040208857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20040208857</sourcerecordid><originalsourceid>FETCH-uspatents_applications_200402088573</originalsourceid><addsrcrecordid>eNqVzEEKwjAQheFuXIh6h9m6EEJV7F4UD6DrMibTEkgmITMVvb219AKuHjw-_mX1fghB6sBSCAKOin-Rg66kCBSf5ZPYWxClOIsuFfBsC6F47kELsuSArKg-MWgKNF6WANlNuFBGX37WYcR-jKsXGWhdLToMQpt5V9X2ermfb7tBMiqxSos5B2-nsLS1MQdTm6Y5nvb_2C_1Gk3b</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue</title><source>USPTO Published Applications</source><creator>Binas, Bert ; Bader, Michael ; Chai, Giuxuan ; Faendrich, Fred ; Ganten, Detlev</creator><creatorcontrib>Binas, Bert ; Bader, Michael ; Chai, Giuxuan ; Faendrich, Fred ; Ganten, Detlev</creatorcontrib><description>The invention relates to the use of cells from cell lines, which are derived from early embryonic stages, for the donor-specific increase in transplantation tolerance and for repairing damaged tissue. Areas of application of the invention include the field of medicine and the pharmaceutical industry. The aim of the invention is to produce a donor-specific immunotolerance in order to prevent a rejection of the transplanted tissue due to an immune response and thus to be able to limit the administration of immune suppressive agents. In order to produce a donor-specific immunotolerance, embryonic stem cell-like cell lines (ECL) are obtained from blastocysts and are transfected with genetic material of the donor, which codes for the MHC haplotypes. The cells produced in such a manner are administered to the recipient before the transplantation for producing an immunotolerance against the tissue to be transplanted or for regenerating already damaged tissue.</description><language>eng</language><creationdate>2004</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20040208857$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,869,881,64035</link.rule.ids><linktorsrc>$$Uhttps://patentcenter.uspto.gov/applications/10433557$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Binas, Bert</creatorcontrib><creatorcontrib>Bader, Michael</creatorcontrib><creatorcontrib>Chai, Giuxuan</creatorcontrib><creatorcontrib>Faendrich, Fred</creatorcontrib><creatorcontrib>Ganten, Detlev</creatorcontrib><title>Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue</title><description>The invention relates to the use of cells from cell lines, which are derived from early embryonic stages, for the donor-specific increase in transplantation tolerance and for repairing damaged tissue. Areas of application of the invention include the field of medicine and the pharmaceutical industry. The aim of the invention is to produce a donor-specific immunotolerance in order to prevent a rejection of the transplanted tissue due to an immune response and thus to be able to limit the administration of immune suppressive agents. In order to produce a donor-specific immunotolerance, embryonic stem cell-like cell lines (ECL) are obtained from blastocysts and are transfected with genetic material of the donor, which codes for the MHC haplotypes. The cells produced in such a manner are administered to the recipient before the transplantation for producing an immunotolerance against the tissue to be transplanted or for regenerating already damaged tissue.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2004</creationdate><recordtype>patent</recordtype><sourceid>EFI</sourceid><recordid>eNqVzEEKwjAQheFuXIh6h9m6EEJV7F4UD6DrMibTEkgmITMVvb219AKuHjw-_mX1fghB6sBSCAKOin-Rg66kCBSf5ZPYWxClOIsuFfBsC6F47kELsuSArKg-MWgKNF6WANlNuFBGX37WYcR-jKsXGWhdLToMQpt5V9X2ermfb7tBMiqxSos5B2-nsLS1MQdTm6Y5nvb_2C_1Gk3b</recordid><startdate>20041021</startdate><enddate>20041021</enddate><creator>Binas, Bert</creator><creator>Bader, Michael</creator><creator>Chai, Giuxuan</creator><creator>Faendrich, Fred</creator><creator>Ganten, Detlev</creator><scope>EFI</scope></search><sort><creationdate>20041021</creationdate><title>Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue</title><author>Binas, Bert ; Bader, Michael ; Chai, Giuxuan ; Faendrich, Fred ; Ganten, Detlev</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_applications_200402088573</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2004</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Binas, Bert</creatorcontrib><creatorcontrib>Bader, Michael</creatorcontrib><creatorcontrib>Chai, Giuxuan</creatorcontrib><creatorcontrib>Faendrich, Fred</creatorcontrib><creatorcontrib>Ganten, Detlev</creatorcontrib><collection>USPTO Published Applications</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Binas, Bert</au><au>Bader, Michael</au><au>Chai, Giuxuan</au><au>Faendrich, Fred</au><au>Ganten, Detlev</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue</title><date>2004-10-21</date><risdate>2004</risdate><abstract>The invention relates to the use of cells from cell lines, which are derived from early embryonic stages, for the donor-specific increase in transplantation tolerance and for repairing damaged tissue. Areas of application of the invention include the field of medicine and the pharmaceutical industry. The aim of the invention is to produce a donor-specific immunotolerance in order to prevent a rejection of the transplanted tissue due to an immune response and thus to be able to limit the administration of immune suppressive agents. In order to produce a donor-specific immunotolerance, embryonic stem cell-like cell lines (ECL) are obtained from blastocysts and are transfected with genetic material of the donor, which codes for the MHC haplotypes. The cells produced in such a manner are administered to the recipient before the transplantation for producing an immunotolerance against the tissue to be transplanted or for regenerating already damaged tissue.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_applications_20040208857
source USPTO Published Applications
title Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A42%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFI&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Binas,%20Bert&rft.date=2004-10-21&rft_id=info:doi/&rft_dat=%3Cuspatents_EFI%3E20040208857%3C/uspatents_EFI%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true